{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+response", "query": { "intervention": "Standard response" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1429, "total_pages": 143, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+response&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T15:05:41.791Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03391466", "title": "Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "BIOLOGICAL" }, { "name": "Platinum-containing Salvage Chemotherapy", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 359, "start_date": "2018-01-25", "completion_date": "2024-11-25", "has_results": true, "last_update_posted_date": "2025-12-01", "last_synced_at": "2026-09-06T15:05:41.791Z", "location_count": 30, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 24 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03391466" }, { "nct_id": "NCT04134728", "title": "Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "GSK3196165 (Otilimab)", "type": "BIOLOGICAL" }, { "name": "Sarilumab", "type": "BIOLOGICAL" }, { "name": "Placebo to GSK3196165/ Sarilumab", "type": "DRUG" }, { "name": "csDMARDs", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 550, "start_date": "2019-10-31", "completion_date": "2022-02-01", "has_results": true, "last_update_posted_date": "2023-07-17", "last_synced_at": "2026-09-06T15:05:41.791Z", "location_count": 46, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04134728" }, { "nct_id": "NCT02420314", "title": "Pharmacological Ascorbate for Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ascorbic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joseph J. Cullen, MD, FACS", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2015-04", "completion_date": "2022-08-27", "has_results": true, "last_update_posted_date": "2024-08-20", "last_synced_at": "2026-09-06T15:05:41.791Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02420314" }, { "nct_id": "NCT05795764", "title": "Crisis Response Planning for Military Personnel", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Suicidal", "Suicide Threat", "Suicidal Ideation" ], "interventions": [ { "name": "Crisis Response Planning", "type": "BEHAVIORAL" }, { "name": "Treatment as Usual", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "United States Naval Medical Center, San Diego", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 700, "start_date": "2023-06-21", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-09-06T15:05:41.791Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05795764" }, { "nct_id": "NCT04686838", "title": "REmote Assessment and Dynamic Response Intervention II", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dementia", "Alzheimer Disease", "Relationship, Marital", "Caregiver Stress Syndrome" ], "interventions": [ { "name": "READyR II: A", "type": "BEHAVIORAL" }, { "name": "READyR II: B", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 30, "start_date": "2021-07-01", "completion_date": "2022-11-25", "has_results": false, "last_update_posted_date": "2023-01-18", "last_synced_at": "2026-09-06T15:05:41.791Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04686838" }, { "nct_id": "NCT05489887", "title": "Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "Naxitamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Giselle Sholler", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 93, "start_date": "2022-09-14", "completion_date": "2036-09", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-06T15:05:41.791Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05489887" }, { "nct_id": "NCT00103285", "title": "Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Childhood B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "9 Years", "sex": "ALL", "summary": "1 Year to 9 Years" }, "enrollment_count": 5377, "start_date": "2005-04-11", "completion_date": "2021-03-31", "has_results": true, "last_update_posted_date": "2021-06-14", "last_synced_at": "2026-09-06T15:05:41.791Z", "location_count": 210, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00103285" }, { "nct_id": "NCT01721226", "title": "CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Human Immunodeficiency Virus" ], "interventions": [ { "name": "Intervention Arm (computer-based CARE+ Corrections tool)", "type": "DEVICE" }, { "name": "Educational video on opiate overdose prevention", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "George Washington University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2013-08", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-02-10", "last_synced_at": "2026-09-06T15:05:41.791Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01721226" }, { "nct_id": "NCT02837315", "title": "Improving Brief Marijuana Interventions With a Behavioral Economic Supplement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Marijuana Use" ], "interventions": [ { "name": "Brief Motivational Intervention (BMI)", "type": "BEHAVIORAL" }, { "name": "Substance-Free Activity Session (SFAS)", "type": "BEHAVIORAL" }, { "name": "Relaxation Session", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Memphis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2014-10-23", "completion_date": "2016-11-30", "has_results": false, "last_update_posted_date": "2017-05-02", "last_synced_at": "2026-09-06T15:05:41.791Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02837315" }, { "nct_id": "NCT06698640", "title": "A Trial of AI-Powered Text Message Outreach on Well-Child Visit Completion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Well Child Visit", "Gaps in Care" ], "interventions": [ { "name": "Automated SMS", "type": "BEHAVIORAL" }, { "name": "Automated SMS + Conversational AI Scheduling Assistance", "type": "BEHAVIORAL" }, { "name": "Traditional Passive Outreach", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Waymark", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "0 Years to 21 Years" }, "enrollment_count": 2821, "start_date": "2025-06-01", "completion_date": "2026-03-17", "has_results": true, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-09-06T15:05:41.791Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06698640" } ] }